The Hitchhiker's guide to virotherapy

Oncotarget

Volumn 3, Issue 8, 2012, Pages 735-736

  Donnelly, Oliver ^a   Vile, Richard ^a,d   Pandha, Hardev ^b   Harrington, Kevin ^c   Melcher, Alan ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC;

ANTIBODY TITER; CANCER CHEMOTHERAPY; CELL SUSPENSION; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLYMERASE CHAIN REACTION; REOVIRUS; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

EID: 84868625757     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.627     Document Type: Editorial

References (9)

1. C.L. White, K.R. Twigger, L. Vidal, et al. Gene Ther 15 (2008) 911.
2. N.N. Senzer, H.L. Kaufman, T. Amatruda, et al. J. Clin. Oncol 27 (2009) 5763.
3. O.G. Donnelly, F. Errington-Mais, R. Prestwich, et al. Curr Pharm Biotechnol (2011).
4. L. Vidal, H.S. Pandha, T.A. Yap, et al. Clinical Cancer Research 14 (2008) 7127.
5. C.J. Breitbach, J. Burke, D. Jonker, et al. Nature 477 (2011) 99.
6. R.A. Adair, V. Roulstone, K.J. Scott, et al. Sci Transl Med 4 (2012) 138ra77.
7. E.J. Ilett, R.J. Prestwich, T. Kottke, et al. Gene Ther. 16 (2009) 689.
8. E.J. Ilett, M. Bárcena, F. Errington-Mais, et al. Clin. Cancer Res. 17 (2011) 2767.
9. K.J. Harrington, R.G. Vile, A. Melcher, et al. Cytokine Growth Factor Rev (2010).